IP Library Granted Patent US 8,168,661
Granted Patent B2
US 8,168,661 · App. 12/464,662 · Granted May 1, 2012

Use of picoplatin to treat colorectal cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,661
App. No.
12/464,662
Granted
May 1, 2012
Kind
B2
Abstract

The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens.

Claims (24)

1. A method of treatment of colorectal cancer, comprising:

administering to a patient afflicted with colorectal cancer, picoplatin, 5-fluorouracil (5-FU), and leucovorin, wherein 5-FU and leucovorin are administered intravenously at least twice at intervals of about 2 weeks and the picoplatin is administered at doses of about 60-180 mg/m 2 with the leucovorin and 5-FU every other time that the fluorouracil and leucovorin are administered, so that a cumulative dose of picoplatin of at least about 900 mg/m 2 is administered.

2. The method of claim 1 wherein the picoplatin is administered at least once at a dosage of about 150 mg/m 2 .

3. The method of claim 1 wherein the patient has not previously been treated for metastatic disease.

4. The method of claim 1 wherein the patient has not previously been treated systemically for metastatic disease.

5. The method of claim 1 wherein the primary tumor is resected or debulked following administration of the picoplatin, the 5-FU and the leucovorin.

6. The method of claim 1 wherein the patient has previously had surgery to resect or de-bulk a colorectal tumor.

7. The method of claim 1 wherein the administration is effective to prevent or delay development or metastasis of the colorectal cancer.

8. The method of claim 1 wherein the picoplatin, when administered, and the leucovorin are administered substantially concurrently.

9. The method of claim 1 wherein the picoplatin, when administered, and the leucovorin are administered simultaneously.

10. The method of claim 1 wherein the 5-FU is administered following the administration of the picoplatin and the leucovorin.

11. The method of claim 1 wherein the leucovorin is administered at a dosage of about 400 mg/m 2 .

12. The method of claim 1 wherein the 5-FU is administered at a total dosage per dosing of about 2000-3000 mg/m 2 .

13. The method of claim 1 wherein the picoplatin is administered at a cumulative dosage of about 900-2000 mg/m 2 .

14. The method of claim 1 wherein a subsequent dose of picoplatin is administered at about a 15-30 mg/m 2 lower dose than a previous dose.

15. The method of claim 14 wherein the picoplatin is administered at least once at a dosage of about 150 mg/m 2 .

16. The method of claim 1 wherein the leucovorin, at a dosage of about 400 mg/m 2 , is administered as a 2 hour infusion, the administration of the leucovorin being followed by a 5-FU bolus at a dosage of about 400 mg/m 2 ; the 5-FU bolus being followed by 5-FU at a dosage of about 2,400 mg/m 2 administered as a 46 hour continuous infusion; wherein the leucovorin and the 5-FU are administered to the patient every 2 weeks and about 60-150 mg/m 2 of the picoplatin is administered to the patient with the leucovorin every 4 weeks, wherein at least the initial dose of picoplatin is about 150 mg/m 2 .

17. The method of claim 1 further comprising administration of a 5-HT 3 receptor antagonist.

18. The method of claim 1 comprising administering the picoplatin in a dosage form comprising an isotonic solution comprising:

(a) water;

(b) a tonicity adjuster; and

(c) about 0.5 mg/mL dissolved picoplatin.

19. A method of treatment of colorectal cancer, comprising:

administering to a patient afflicted with colorectal cancer effective amounts of a combination of picoplatin, 5-FU and leucovorin, wherein the picoplatin, 5-FU and leucovorin are administered intravenously at least twice at intervals of about two weeks, wherein the amount of picoplatin administered every two weeks is 40-75 mg/m 2 .

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2016
From: TALLIKUT PHARMACEUTICALS, INC.
To: ACCELERATED PHARMA, INC.
Reel/Frame 038528/0599 →
MERGER Recorded Dec 9, 2014
From: ENCARTA, INC.
To: TALLIKUT PHARMACEUTICALS, INC.
Reel/Frame 034436/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: PONIARD PHARMACEUTICALS, INC.
To: PONIARD (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 034438/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: PONIARD (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: ENCARTA, INC.
Reel/Frame 034439/0341 →
RELEASE OF SECURITY INTEREST Recorded May 21, 2014
From: SCHWEGMAN, LUNDBERG& WOESSNER, P.A.
To: POINARD PHARMACEUTICALS, INC.
Reel/Frame 032981/0663 →
LIEN Recorded Apr 16, 2012
From: PONAIRD PHARMACEUTICALS, INC.
To: SCHWEGMAN, LUNDBERG& WOESSNER, P.A.
Reel/Frame 028052/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2009
From: KARLIN, DAVID A.; BREITZ, HAZEL B.; WEIDEN, PAUL L.
To: PONIARD PHARMACEUTICALS, INC.
Reel/Frame 022963/0398 →